<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Acute coronary syndrome: Oral anticoagulation in medically treated patients</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Acute coronary syndrome: Oral anticoagulation in medically treated patients</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Acute coronary syndrome: Oral anticoagulation in medically treated patients</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Gregory YH Lip, MD, FRCPE, FESC, FACC</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Freek Verheugt, MD, FACC, FESC</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Christopher P Cannon, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd F Dardas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 15, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>All patients with an acute coronary syndrome (ACS) (see  <a class="medical medical_review" href="/z/d/html/52.html" rel="external">"Diagnosis of acute myocardial infarction", section on 'Definitions'</a>), irrespective of whether or not percutaneous coronary intervention (PCI) with stenting is performed, benefit from antiplatelet therapy with <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> and a P2Y<sub>12</sub> inhibitor. (See  <a class="medical medical_review" href="/z/d/html/95.html" rel="external">"Acute non-ST-elevation acute coronary syndromes: Early antiplatelet therapy", section on 'Duration'</a> and  <a class="medical medical_review" href="/z/d/html/94.html" rel="external">"Acute ST-elevation myocardial infarction: Antiplatelet therapy", section on 'Duration of dual antiplatelet therapy'</a>.)</p><p>This topic will address two clinically important questions for ACS patients who are treated medically (no PCI) and are discharged from the hospital: </p><p class="bulletIndent1"><span class="glyph">●</span>Does chronic oral anticoagulant therapy (OAC), with or without antiplatelet therapy, have a role?</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In ACS patients who are receiving long-term OAC for an indication such as atrial fibrillation (AF) or deep vein thrombosis, what is the optimal antithrombotic regimen?</p><p></p><p>The approach to combined antithrombotic therapy in patients receiving OAC who have undergone PCI is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1535.html" rel="external">"Coronary artery disease patients requiring combined anticoagulant and antiplatelet therapy"</a>.)</p><p>The use of parenteral anticoagulants at the time of presentation for ACS is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/92.html" rel="external">"Acute ST-elevation myocardial infarction: Management of anticoagulation", section on 'Summary and recommendations'</a> and  <a class="medical medical_review" href="/z/d/html/93.html" rel="external">"Anticoagulant therapy in non-ST elevation acute coronary syndromes", section on 'Summary and recommendations'</a>.)</p><p class="headingAnchor" id="H169516629"><span class="h1">POTENTIAL ROLE OF ORAL ANTICOAGULANTS IN UNSTENTED ACUTE CORONARY SYNDROME PATIENTS</span><span class="headingEndMark"> — </span>The rationale for possible benefit from chronic anticoagulant therapy for the prevention of recurrent ischemic events comes in part from the following observations:</p><p class="bulletIndent1"><span class="glyph">●</span>The high rates of recurrent ischemic events after ACS are due, at least in part, to a persistent thrombotic risk within the coronary circulation. This thrombotic risk stems from heightened platelet reactivity, an increase in activity of some or all of the elements of the coagulation cascade, or both [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/z/d/html/1371.html" rel="external">"Overview of hemostasis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There is persistent elevation of markers of thrombin generation for as long as six months after ACS [<a href="#rid2">2</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serial angioscopy of culprit plaques (after myocardial infarction [MI]) shows persistence of thrombus at 1, 6, and 18 months (64, 5, and 12 percent, respectively) [<a href="#rid3">3</a>]. (See  <a class="medical medical_review" href="/z/d/html/115790.html" rel="external">"Mechanisms of acute coronary syndromes related to atherosclerosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Vulnerable plaques are characterized by repeated plaque microruptures, followed by subclinical thrombosis [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In small angiographic follow-up studies of ACS patients treated with either <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> or <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a>, lesion progression was significantly reduced in the warfarin group [<a href="#rid1">1,5</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Local synthesis of several functionally active coagulation proteins has been demonstrated in human atherosclerotic lesions. These proteins may be involved in atherogenesis, as indicated by increased thrombi-generating activity in early atherosclerotic lesions [<a href="#rid4">4</a>].</p><p></p><p class="headingAnchor" id="H3108296615"><span class="h2">Evidence</span><span class="headingEndMark"> — </span>Available oral anticoagulants include <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> and four direct-acting oral anticoagulants (DOAC; also referred to as non-vitamin K oral anticoagulants [NOAC]): <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">rivaroxaban</a>, <a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">dabigatran</a>, <a class="drug drug_general" data-topicid="99275" href="/z/d/drug information/99275.html" rel="external">edoxaban</a>, and <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">apixaban</a>. (See  <a class="medical medical_review" href="/z/d/html/1334.html" rel="external">"Warfarin and other VKAs: Dosing and adverse effects"</a> and  <a class="medical medical_review" href="/z/d/html/1370.html" rel="external">"Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: Dosing and adverse effects"</a>.)</p><p>Among the OACs, only <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">rivaroxaban</a> has been shown to reduce the risk of recurrent ischemic events, including mortality, when added to dual antiplatelet therapy (DAPT) in patients with ACS who have not undergone percutaneous coronary intervention (PCI) with stenting. However, there is an important increase in major bleeding risk. </p><p class="headingAnchor" id="H3770019"><span class="h3">Rivaroxaban</span><span class="headingEndMark"> — </span>Adding low-dose <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">rivaroxaban</a> to <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> and <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> in patients with ACS who are not at high risk of bleeding is a reasonable strategy based primarily on the ATLAS 2 ACS-TIMI 51 trial presented below. In that study, rivaroxaban at a dose of 2.5 mg twice daily improved mortality in patients with recent ACS when added to aspirin and clopidogrel. However, such therapy significantly increases the risk of major bleeding and intracranial hemorrhage. </p><p>It should be kept in mind that the level of anticoagulation achieved with either a 2.5 or 5 mg twice-daily dose is less than that seen with the 20 mg once-daily dose, as is used in patients with AF (or 15 mg in those on triple therapy). Thus, at this dose, it is not strictly "anticoagulation" but rather low-dose factor Xa inhibition.  </p><p>The ATLAS 2 ACS-TIMI 51 trial randomly assigned 15,526 patients with recent ACS to either twice-daily doses of 2.5 mg or 5 mg ("very low" and "low dose," respectively) of <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">rivaroxaban</a> or placebo [<a href="#rid6">6</a>]. These doses are one-quarter and one-half of the full anticoagulation dose. All patients were intended to receive DAPT with <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> and either <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> or <a class="drug drug_general" data-topicid="9996" href="/z/d/drug information/9996.html" rel="external">ticlopidine</a> (<a class="drug drug_general" data-topicid="16784" href="/z/d/drug information/16784.html" rel="external">ticagrelor</a> and <a class="drug drug_general" data-topicid="9533" href="/z/d/drug information/9533.html" rel="external">prasugrel</a> were not prescribed); 93 percent of patients ultimately received DAPT. Approximately 40 percent of patients did not undergo revascularization. The primary efficacy endpoint was a composite of death from cardiovascular causes, MI, or stroke. The following outcomes (comparing drug with placebo) were seen after a mean duration of treatment of 13.1 months:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">Rivaroxaban</a> (both doses combined) significantly reduced the rate of primary efficacy endpoint (8.9 versus 10.7 percent; hazard ratio [HR] 0.84, 95% CI 0.74-0.96). These rates for the 2.5 mg and 5 mg doses of rivaroxaban were 9.1 and 8.8 percent, respectively.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The rates of death from cardiovascular cause or any cause were significantly reduced with the 2.5 mg dose (2.7 versus 4.1 and 2.9 versus 4.5 percent, respectively). This survival benefit was not seen with the 5 mg dose. Both doses of <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">rivaroxaban</a> significantly reduced the rate of stent thrombosis by about 31 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">Rivaroxaban</a> significantly increased the rate of TIMI major bleeding not related to coronary artery bypass grafting (2.1 versus 0.6 percent; HR 3.96, 95% CI 2.46-6.38). These rates for the 2.5 mg and 5 mg doses of rivaroxaban were 1.8 and 2.4 percent, respectively. Rivaroxaban also increased the rate of intracranial hemorrhage (0.6 versus 0.2 percent; p = 0.009).</p><p></p><p>The smaller GEMINI-ACS-1 trial randomly assigned 3037 ACS patients to either <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> 100 mg daily or <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">rivaroxaban</a> 2.5 mg twice daily within 10 days of hospitalization; both groups had received aspirin plus a P2Y<sub>12</sub> receptor blocker (<a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> or <a class="drug drug_general" data-topicid="16784" href="/z/d/drug information/16784.html" rel="external">ticagrelor</a>), and both groups continued after randomization with the latter [<a href="#rid7">7</a>]. After a median treatment duration of 291 days, TIMI non-coronary artery bypass graft clinically significant bleeding was similar in the two groups (5 percent; HR 1.09, 95% CI 0.80-1.50). The study was not powered to assess efficacy. </p><p class="headingAnchor" id="H759484566"><span class="h3">Apixaban</span><span class="headingEndMark"> — </span>The APPRAISE-2 trial randomly assigned 7392 patients with an ACS to either <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">apixaban</a> 5 mg twice daily (the full anticoagulant dose) or placebo in addition to <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> or DAPT. Over 50 percent of patients did not undergo PCI with stenting. The trial was stopped early due to a significant increase in the rate of major bleeding in the apixaban group [<a href="#rid8">8</a>]. At a median follow-up of 241 days, the primary endpoint of cardiovascular death, MI, or ischemic stroke occurred in a similar percent of patients in the apixaban and placebo groups (7.5 versus 7.9, respectively), while the primary safety outcome of TIMI major bleeding occurred significantly more often in the group that received apixaban (1.3 versus 0.5 percent) [<a href="#rid9">9</a>]. These findings were consistent in all subgroups, including those stratified by use of revascularization (55 percent of patients underwent medical management without revascularization).</p><p class="headingAnchor" id="H577645963"><span class="h3">Dabigatran</span><span class="headingEndMark"> — </span>We do not recommend the addition of <a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">dabigatran</a> to antiplatelet therapy in ACS patients who did not undergo stenting. Dabigatran has not been evaluated for efficacy in the setting of ACS and thus we do not recommend its use. With regard to safety, the phase II RE-DEEM trial randomly assigned 1861 MI patients on DAPT to dabigatran or placebo. There was a significant dose-dependent increase in the risk of major or clinically relevant minor bleeding during the six-month treatment period [<a href="#rid10">10</a>]. </p><p class="headingAnchor" id="H130597163"><span class="h3">Edoxaban</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="99275" href="/z/d/drug information/99275.html" rel="external">Edoxaban</a> has not been evaluated in ACS patients who have not undergone PCI with stenting. </p><p class="headingAnchor" id="H1459218562"><span class="h3">Warfarin</span><span class="headingEndMark"> — </span>There are no studies comparing <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> plus DAPT with DAPT alone or with warfarin plus a single antiplatelet agent. The evidence presented below regarding the role of warfarin in ACS patients has limited applicability to current practice for the following reasons:</p><p class="bulletIndent1"><span class="glyph">●</span>They were performed before the current era in which the great majority of patients with ACS are treated with an early invasive strategy PCI with stenting [<a href="#rid11">11</a>]. (See  <a class="medical medical_review" href="/z/d/html/46.html" rel="external">"Non-ST-elevation acute coronary syndromes: Selecting an approach to revascularization"</a> and  <a class="medical medical_review" href="/z/d/html/72.html" rel="external">"Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>They were performed before the current era in which most patients with an ACS are treated with DAPT with <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> plus a platelet P2Y<sub>12</sub> inhibitor. (See  <a class="medical medical_review" href="/z/d/html/95.html" rel="external">"Acute non-ST-elevation acute coronary syndromes: Early antiplatelet therapy", section on 'P2Y12 use'</a> and  <a class="medical medical_review" href="/z/d/html/94.html" rel="external">"Acute ST-elevation myocardial infarction: Antiplatelet therapy", section on 'Patients receiving fibrinolytic therapy'</a>.)</p><p></p><p>Keeping these limitations in mind, efficacy and safety outcomes have been evaluated in ACS patients treated with <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> alone, <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> alone, and therapy with both. The available evidence suggests that combined therapy may reduce the risk of ischemic events compared with aspirin alone when the international normalized ratio (INR) is strictly maintained between 2 and 3. As combined therapy also increases the risk of bleeding compared with monotherapy, the benefit with warfarin is partially offset. (See  <a class="medical medical_review" href="/z/d/html/1535.html" rel="external">"Coronary artery disease patients requiring combined anticoagulant and antiplatelet therapy", section on 'Bleeding'</a>.)</p><p>Two meta-analyses of trials that compared <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> plus <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> with aspirin alone came to a similar conclusion: Among ACS patients at low or intermediate risk for bleeding, the benefits (reduction in ischemic events) of adding warfarin to aspirin outweigh the bleeding risks <strong>only when the</strong> <strong>attained INR is 2 to 3</strong> [<a href="#rid11">11,12</a>].</p><p class="headingAnchor" id="H7962934"><span class="h2">Our approach</span><span class="headingEndMark"> — </span>For patients with ACS who have been managed medically (without intracoronary stenting) and who do not have other indications for chronic anticoagulant therapy, there are two reasonable options for antithrombotic therapy based on the evidence presented above:</p><p class="bulletIndent1"><span class="glyph">●</span>The <strong>established </strong>approach with <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> and <a class="drug drug_general" data-topicid="16784" href="/z/d/drug information/16784.html" rel="external">ticagrelor</a> for one year followed by aspirin alone. <a class="drug drug_general" data-topicid="9533" href="/z/d/drug information/9533.html" rel="external">Prasugrel</a> has not been shown to improve outcomes in this setting. In patients at higher bleeding risk, <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> can be used instead of ticagrelor. (See  <a class="medical medical_review" href="/z/d/html/94.html" rel="external">"Acute ST-elevation myocardial infarction: Antiplatelet therapy", section on 'Patients not reperfused'</a> and  <a class="medical medical_review" href="/z/d/html/95.html" rel="external">"Acute non-ST-elevation acute coronary syndromes: Early antiplatelet therapy", section on 'Ischemia-guided management'</a>.)</p><p></p><p class="bulletIndent1">After one year, we continue with <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>. In patients at high thrombotic risk, such as those with multiple myocardial infarctions, left main stenting, or multiple stents, we consider extending aspirin and <a class="drug drug_general" data-topicid="16784" href="/z/d/drug information/16784.html" rel="external">ticagrelor</a> 60 mg twice daily for an additional 18 months as was evaluated in the PEGASUS 54 trial. (See  <a class="medical medical_review" href="/z/d/html/1572.html" rel="external">"Long-term antiplatelet therapy after coronary artery stenting in stable patients"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">Rivaroxaban</a> 2.5 mg twice daily in addition to <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> and <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> 75 mg daily for about one year in patients at high thrombotic risk and not at high bleeding risk. High-bleeding-risk patients should not receive rivaroxaban in this setting if one of the following are present: age &gt;75 years, history of stroke or gastrointestinal bleeding, hepatic or renal disease, malignancy, or excessive fall risk. This regimen has not been approved by the U S Food and Drug administration. (See  <a class="medical medical_review" href="/z/d/html/1505.html" rel="external">"Prevention of cardiovascular disease events in those with established disease (secondary prevention) or at very high risk", section on 'Anticoagulant therapy'</a> and <a class="local">'Rivaroxaban'</a> above.)</p><p></p><p class="bulletIndent1">After one year, we omit <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> and continue with <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">rivaroxaban</a> 2.5 mg twice daily and <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> (see <a class="local">'Rivaroxaban'</a> above). Other factors such as baseline anemia or hypertension are relative contraindications that become absolute as their severity worsens. We are uncertain as to how to properly identify which moderate-bleeding-risk patients might benefit from rivaroxaban. Practitioners should have a detailed discussion about the relative benefits and risks of adding rivaroxaban to aspirin plus clopidogrel with potential candidates. After one year, we reassess the relative ischemic and bleeding risks. Some patients are candidates for long-term therapy with rivaroxaban and aspirin while in others it may be appropriate to consider only aspirin.</p><p></p><p>Some ACS patients will not receive DAPT, usually due to allergy to either <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> or platelet P2Y<sub>12</sub> receptor blocker. We suggest referral to a specialist (often an allergist) familiar with the management of these patients. (See  <a class="medical medical_review" href="/z/d/html/2082.html" rel="external">"NSAIDs (including aspirin): Allergic and pseudoallergic reactions", section on 'Management'</a> and  <a class="medical medical_review" href="/z/d/html/2085.html" rel="external">"Diagnostic challenge and desensitization protocols for NSAID reactions"</a> and  <a class="medical medical_review" href="/z/d/html/520.html" rel="external">"Aspirin-exacerbated respiratory disease"</a> and  <a class="medical medical_review" href="/z/d/html/1576.html" rel="external">"Antithrombotic therapy for elective percutaneous coronary intervention: General use", section on 'Problems with clopidogrel use'</a>.)</p><p>For patients who cannot receive DAPT, we make the following recommendations:</p><p class="bulletIndent1"><span class="glyph">●</span>For those patients who cannot take a platelet P2Y<sub>12</sub> inhibitor and those in whom the risk of bleeding  (<a class="graphic graphic_table graphicRef75259" href="/z/d/graphic/75259.html" rel="external">table 1</a>) due to long-term therapy with both antiplatelet and anticoagulant drugs is acceptable, we believe the addition of low-dose <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">rivaroxaban</a> to <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> is reasonable. This is based on the small portion of patients in the ATLAS 2 ACS-TIMI 51 trial (see <a class="local">'Rivaroxaban'</a> above) who did not receive DAPT. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For the uncommon patient who cannot take <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>, we use <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> alone, as was carried out in the CAPRIE trial. (See  <a class="medical medical_review" href="/z/d/html/110006.html" rel="external">"Aspirin for the secondary prevention of atherosclerotic cardiovascular disease", section on 'Alternatives to aspirin'</a>.)  </p><p></p><p>Patients who have had no recurrent ischemic episodes through one year are considered to have stable coronary artery disease. We continue <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">rivaroxaban</a> monotherapy based on the AFIRE trial. This issue is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1535.html" rel="external">"Coronary artery disease patients requiring combined anticoagulant and antiplatelet therapy", section on 'Long-term therapy studies'</a>.) </p><p class="headingAnchor" id="H22846480"><span class="h1">BLEEDING RISK</span><span class="headingEndMark"> — </span>For patients who require oral anticoagulant plus antiplatelet (<a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> and/or P2Y<sub>12</sub> receptor blocker) therapy, the bleeding risk is increased significantly compared with either therapy alone. This issue is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/1535.html" rel="external">"Coronary artery disease patients requiring combined anticoagulant and antiplatelet therapy", section on 'Bleeding'</a>.)</p><p class="headingAnchor" id="H3648757366"><span class="h1">PATIENTS WHO REQUIRE ORAL ANTICOAGULANT</span><span class="headingEndMark"> — </span>The optimal antithrombotic approach in ACS patients with a long-term indication for oral anticoagulants (OAC), such as those with atrial fibrillation (AF) or deep vein thrombosis, who are treated medically (no percutaneous coronary intervention) is not known.</p><p>We discharge these patients on OAC plus <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> 75 mg daily and treat for one year. In patients at very high thrombotic risk who are not at high bleeding risk, we consider adding <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> for one month. </p><p>We prefer DOACs to <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> and we use full-dose DOAC rather than low-dose <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">rivaroxaban</a> in this setting. <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">Clopidogrel</a> is the only P2Y<sub>12 </sub>inhibitor we use with full-dose OAC, as there would be a very high risk of a bleeding complication if <a class="drug drug_general" data-topicid="9533" href="/z/d/drug information/9533.html" rel="external">prasugrel</a> or <a class="drug drug_general" data-topicid="16784" href="/z/d/drug information/16784.html" rel="external">ticagrelor</a> were used instead of clopidogrel. OAC plus <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> for one year is a reasonable alternative to OAC plus clopidogrel. </p><p>Support for this approach comes from the AUGUSTUS trial, which is discussed in detail separately. In AUGUSTUS, which used a two-by-two factorial design to compare <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">apixaban</a> (at a dose labelled for stroke prevention) with vitamin K antagonists and <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> with placebo, 1097 patients (23.9 percent of the patients enrolled) had an acute coronary syndrome treated medically [<a href="#rid13">13</a>]. In this prespecified subgroup analysis, apixaban compared with vitamin K antagonist reduced major or clinically relevant nonmajor bleeding (hazard ratio [HR] 0.44, 95% CI 0.28-0.687), and there was a similar effect on the individual endpoints of death and ischemic events in both groups. Compared with placebo, aspirin had an almost significantly higher rate of bleeding than placebo (HR 1.49, 95% CI 0.98-2.26) and similar rates of ischemic events. These results were consistent with the main AUGUSTUS trial outcomes. (See  <a class="medical medical_review" href="/z/d/html/1535.html" rel="external">"Coronary artery disease patients requiring combined anticoagulant and antiplatelet therapy", section on 'Post-discharge studies'</a>.)</p><p>For patients who have completed the 12 months of antithrombotic therapy, long-term antithrombotic therapy with either OAC monotherapy or OAC plus an antiplatelet agent is reasonable. In patients at the end of the spectrum where bleeding risk is high and ischemic risk is low, long-term DOAC monotherapy makes sense. On the other hand, for patients at high ischemic risk and low bleeding risk, DOAC plus a single antiplatelet agent makes sense. The strategy of DOAC alone is supported by the AFIRE trial, which enrolled stable patients. (See  <a class="medical medical_review" href="/z/d/html/1535.html" rel="external">"Coronary artery disease patients requiring combined anticoagulant and antiplatelet therapy", section on 'Long-term therapy studies'</a>.) </p><p class="headingAnchor" id="H3836021848"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/114034.html" rel="external">"Society guideline links: Non-ST-elevation acute coronary syndromes (non-ST-elevation myocardial infarction)"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/113180.html" rel="external">"Society guideline links: ST-elevation myocardial infarction (STEMI)"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/114614.html" rel="external">"Society guideline links: Anticoagulation"</a>.) </p><p class="headingAnchor" id="H10159433"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/16265.html" rel="external">"Patient education: Choosing an oral medicine for blood clots (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/86638.html" rel="external">"Patient education: Taking oral medicines for blood clots (The Basics)"</a>) </p><p></p><p class="headingAnchor" id="H10157891"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with an acute coronary syndrome (ACS) who have been treated medically (no percutaneous coronary artery intervention with stenting), there are two clinical situations in which oral anticoagulant (OAC) therapy is either needed or may be useful:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients in whom the addition of OAC may improve clinical outcomes. (See <a class="local">'Potential role of oral anticoagulants in unstented acute coronary syndrome patients'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with a long-term need for OAC. (See <a class="local">'Patients who require oral anticoagulant'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For ACS patients managed medically who do not have an indication for chronic OAC (the first group above), the following two strategies for the first year of antithrombotic therapy are reasonable. Patient preference may play an important role in deciding between the two (see <a class="local">'Our approach'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">Aspirin</a> and <a class="drug drug_general" data-topicid="16784" href="/z/d/drug information/16784.html" rel="external">ticagrelor</a>. <a class="drug drug_general" data-topicid="9533" href="/z/d/drug information/9533.html" rel="external">Prasugrel</a> has not been shown to improve outcomes in this setting. In patients at higher bleeding risk, <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> can be used instead of ticagrelor. Aspirin alone is given after one year.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">Rivaroxaban</a> 2.5 mg twice daily in addition to <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> and <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> 75 mg daily in patients not at high bleeding risk. If this approach is used, we continue aspirin alone after one year.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For ACS patients managed medically who are receiving long-term OAC for an indication such as atrial fibrillation (the second group above), we suggest full-dose non-vitamin K oral anticoagulant plus <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> 75 mg daily for one year rather than <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> plus clopidogrel 75 mg daily (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Patients who require oral anticoagulant'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients who have completed the 12 months of antithrombotic therapy, long-term antithrombotic therapy with either OAC monotherapy or OAC plus an antiplatelet agent is reasonable. In patients at the end of the spectrum where bleeding risk is high and ischemic risk is low, long-term direct acting oral anticoagulants (DOAC; also referred to as non-vitamin K oral anticoagulants [NOAC]) monotherapy makes sense. On the other hand, for patients at high ischemic risk and low bleeding risk, DOAC plus a single antiplatelet agent makes sense. The strategy of DOAC alone is supported by the AFIRE trial, which enrolled stable patients. (See  <a class="medical medical_review" href="/z/d/html/1535.html" rel="external">"Coronary artery disease patients requiring combined anticoagulant and antiplatelet therapy", section on 'Long-term therapy studies'</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Williams MJ, Morison IM, Parker JH, Stewart RA. Progression of the culprit lesion in unstable coronary artery disease with warfarin and aspirin versus aspirin alone: preliminary study. J Am Coll Cardiol 1997; 30:364.</a></li><li><a class="nounderline abstract_t">Merlini PA, Bauer KA, Oltrona L, et al. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 1994; 90:61.</a></li><li><a class="nounderline abstract_t">Ueda Y, Asakura M, Yamaguchi O, et al. The healing process of infarct-related plaques. Insights from 18 months of serial angioscopic follow-up. J Am Coll Cardiol 2001; 38:1916.</a></li><li><a class="nounderline abstract_t">Borissoff JI, Spronk HM, ten Cate H. The hemostatic system as a modulator of atherosclerosis. N Engl J Med 2011; 364:1746.</a></li><li><a class="nounderline abstract_t">Williams MJ, Stewart RA. Coronary artery flow ten weeks after myocardial infarction or unstable angina: effects of combined warfarin and aspirin therapy. Int J Cardiol 1999; 69:19.</a></li><li><a class="nounderline abstract_t">Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366:9.</a></li><li><a class="nounderline abstract_t">Ohman EM, Roe MT, Steg PG, et al. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. Lancet 2017.</a></li><li><a class="nounderline abstract_t">Alexander JH, Lopes RD, James S, et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011; 365:699.</a></li><li><a class="nounderline abstract_t">Chesebro JH, Knatterud G, Roberts R, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 1987; 76:142.</a></li><li><a class="nounderline abstract_t">Oldgren J, Budaj A, Granger CB, et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J 2011; 32:2781.</a></li><li><a class="nounderline abstract_t">Rothberg MB, Celestin C, Fiore LD, et al. Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit. Ann Intern Med 2005; 143:241.</a></li><li><a class="nounderline abstract_t">Andreotti F, Testa L, Biondi-Zoccai GG, Crea F. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients. Eur Heart J 2006; 27:519.</a></li><li><a class="nounderline abstract_t">Windecker S, Lopes RD, Massaro T, et al. Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial. Circulation 2019; 140:1921.</a></li></ol></div><div id="topicVersionRevision">Topic 101 Version 43.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9247506" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Progression of the culprit lesion in unstable coronary artery disease with warfarin and aspirin versus aspirin alone: preliminary study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8026047" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Persistent activation of coagulation mechanism in unstable angina and myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11738294" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The healing process of infarct-related plaques. Insights from 18 months of serial angioscopic follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21542745" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The hemostatic system as a modulator of atherosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10362368" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Coronary artery flow ten weeks after myocardial infarction or unstable angina: effects of combined warfarin and aspirin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22077192" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Rivaroxaban in patients with a recent acute coronary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28325638" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21780946" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Apixaban with antiplatelet therapy after acute coronary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3109764" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21551462" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16103468" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16143706" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31557056" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
